CD8A and neoplasm: After 9 days of tumor growth, we found that CD8 T-cells harvested from mice receiving both AdV-tk/GCV and cytoreductive surgery inhibited tumor growth more potently than CD8 T-cells from other treatment groups; p = 0.02 (Figure 4A).